GOSSAMER BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
GOSSAMER BIO, INC. (GOSS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 55.54 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-13
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 6.25M shares, a 1322.94% increase year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 49.29M shares, a 9229.79% increase year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 271.12K shares, a 74.97% decline year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 37.80K shares, a 91.42% decline year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 1.28M shares, a 42.39% decline from fiscal 2024.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 2.22M shares, a 79.89% decline from fiscal 2023.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 11.02M shares, a 1062.44% increase from fiscal 2022.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 948.06K shares, a 66.14% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 6.25M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 55.54M shares 10-Q · filed 2026-08-13 | 55.81M shares derived: sum of 3 quarters · filed 2026-08-13 | 55.85M shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 49.29M shares 10-Q · filed 2026-05-15 | 49.56M shares derived: sum of 2 quarters · filed 2026-05-15 | 49.60M shares derived: sum of 3 quarters · filed 2026-05-15 | 50.04M shares derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | 271.12K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 308.91K shares derived: sum of 2 quarters · filed 2026-03-17 | 748.28K shares derived: sum of 3 quarters · filed 2026-03-17 | 1.28M shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 37.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 477.17K shares derived: sum of 2 quarters · filed 2025-11-05 | 1.01M shares 10-Q · filed 2025-11-05 | 2.09M shares derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-06-30 | 439.37K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 967.68K shares 10-Q · filed 2025-08-05 | 2.05M shares derived: sum of 3 quarters · filed 2026-03-17 | 2.49M shares derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-03-31 | 528.31K shares 10-Q · filed 2025-05-15 | 1.61M shares derived: sum of 2 quarters · filed 2026-03-17 | 2.05M shares derived: sum of 3 quarters · filed 2026-03-17 | 2.67M shares derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-12-31 | 1.08M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 1.52M shares derived: sum of 2 quarters · filed 2026-03-17 | 2.14M shares derived: sum of 3 quarters · filed 2026-03-17 | 2.22M shares 10-K · filed 2026-03-17 |
| 2024-09-30 | 440.27K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 1.06M shares derived: sum of 2 quarters · filed 2024-11-07 | 1.13M shares 10-Q · filed 2024-11-07 | 1.38M shares derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | 617.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 692.67K shares 10-Q · filed 2024-08-12 | 934.86K shares derived: sum of 3 quarters · filed 2026-03-17 | 2.39M shares derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | 74.79K shares 10-Q · filed 2024-05-07 | 316.99K shares derived: sum of 2 quarters · filed 2026-03-17 | 1.78M shares derived: sum of 3 quarters · filed 2026-03-17 | 10.67M shares derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | 242.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 1.70M shares derived: sum of 2 quarters · filed 2026-03-17 | 10.59M shares derived: sum of 3 quarters · filed 2026-03-17 | 11.02M shares 10-K · filed 2026-03-17 |
| 2023-09-30 | 1.46M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 10.35M shares derived: sum of 2 quarters · filed 2023-11-09 | 10.78M shares 10-Q · filed 2023-11-09 | 10.90M shares derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | 8.89M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 9.32M shares 10-Q · filed 2023-08-08 | 9.44M shares derived: sum of 3 quarters · filed 2025-03-13 | 9.70M shares derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | 425.81K shares 10-Q · filed 2023-05-09 | 549.97K shares derived: sum of 2 quarters · filed 2025-03-13 | 811.41K shares derived: sum of 3 quarters · filed 2025-03-13 | 1.26M shares derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | 124.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 385.60K shares derived: sum of 2 quarters · filed 2025-03-13 | 833.45K shares derived: sum of 3 quarters · filed 2025-03-13 | 948.06K shares 10-K · filed 2025-03-13 |
| 2022-09-30 | 261.44K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 709.29K shares derived: sum of 2 quarters · filed 2022-11-03 | 823.90K shares 10-Q · filed 2022-11-03 | 1.12M shares derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | 447.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 562.46K shares 10-Q · filed 2022-08-09 | 859.15K shares derived: sum of 3 quarters · filed 2024-03-05 | 1.92M shares derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | 114.61K shares 10-Q · filed 2022-05-10 | 411.31K shares derived: sum of 2 quarters · filed 2024-03-05 | 1.47M shares derived: sum of 3 quarters · filed 2024-03-05 | 2.69M shares derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | 296.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | 1.35M shares derived: sum of 2 quarters · filed 2024-03-05 | 2.58M shares derived: sum of 3 quarters · filed 2024-03-05 | 2.80M shares 10-K · filed 2024-03-05 |
| 2021-09-30 | 1.06M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 2.28M shares derived: sum of 2 quarters · filed 2021-11-08 | 2.50M shares 10-Q · filed 2021-11-08 | 3.48M shares derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-06-30 | 1.23M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | 1.45M shares 10-Q · filed 2021-08-09 | 2.43M shares derived: sum of 3 quarters · filed 2023-03-17 | 2.62M shares derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-03-31 | 220.66K shares 10-Q · filed 2021-05-06 | 1.20M shares derived: sum of 2 quarters · filed 2023-03-17 | 1.39M shares derived: sum of 3 quarters · filed 2023-03-17 | 1.87M shares derived: sum of 4 quarters · filed 2023-03-17 |
| 2020-12-31 | 979.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | 1.17M shares derived: sum of 2 quarters · filed 2023-03-17 | 1.65M shares derived: sum of 3 quarters · filed 2023-03-17 | 1.71M shares 10-K · filed 2023-03-17 |
| 2020-09-30 | 193.44K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | 668.11K shares derived: sum of 2 quarters · filed 2020-11-10 | 735.01K shares 10-Q · filed 2020-11-10 | 803.65K shares derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | 474.67K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | 541.57K shares 10-Q · filed 2020-08-11 | 610.22K shares derived: sum of 3 quarters · filed 2022-03-03 | 873.56K shares derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-03-31 | 66.90K shares 10-Q · filed 2020-05-12 | 135.54K shares derived: sum of 2 quarters · filed 2022-03-03 | 398.89K shares derived: sum of 3 quarters · filed 2022-03-03 | |
| 2019-12-31 | 68.64K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | 331.99K shares derived: sum of 2 quarters · filed 2022-03-03 | 344.30K shares 10-K · filed 2022-03-03 | |
| 2019-09-30 | 263.35K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | 275.66K shares 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | 12.31K shares 10-Q · filed 2019-08-08 | |||
| 2018-12-31 | 36.22K shares 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |